Latest News & Features
Big Pharma
China has introduced new measures to enforce a patent linkage system and proposed draft rules on how a patent owner can challenge the approval of a drug. 11 February 2021
article
Patents and other forms of IP have traditionally been the main way pharmaceutical and biotech companies have secured markets and ensured freedom to operate. 2020 has seen a shift towards licensing deals from some of the leading names in Life Sciences, will this trend continue? 11 February 2021
Big Pharma
The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report. 10 February 2021
Americas
The US Court of Appeals for the Federal Circuit has upheld a decision by a district court that an inventor cannot further extend his shoulder surgery patent after already being granted a term adjustment period by the US Patent and Trademark Office. 9 February 2021
Americas
Johnson & Johnson has settled its case against Advanced Inventory Management, trading as eSutures, which it accused of distributing counterfeit and contaminated surgical tools. 9 February 2021
Europe
Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter. 8 February 2021
Biotechnology
Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides. 5 February 2021
Big Pharma
Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion. 4 February 2021
Big Pharma
Chinese drug maker Qilu’s proposed generic version of a cancer treatment infringes three patents, according to a lawsuit filed by Boehringer Ingelheim. 4 February 2021
Big Pharma
Coherus Biosciences has signed a deal with Chinese biopharmaceutical company Shanghai Junshi Biosciences for the development and commercialisation rights to toripalimab, Junshi’s PD-1 inhibitor, in the US and Canada. 4 February 2021